Last checked at 
NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor -
Portfolio company, PDS Biotechnology Corp, announces updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor in two groups of advanced cancer patients with various types of human papillomavirus 16-positive cancers. Says 75% of immune checkpoint inhibitor naïve patients remain alive at 36 months. In the ICI resistant group, the 12-month OS rate was 72% and the triple combination achieved a median OS of approximately 20 months.
Current stock price: 57.50p
12-month change: down 4%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved
